1 R140 1145th HudziakM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. Effects p185HER2 monoclonal rpern Antiproliferative in vitro and sensitizes cancer cells in a tumor necrosis factor. Mol Cell Biol 1989 9:1165 1172nd Hurwitz E, Stancovski I, Sela M, Y. Yarden oppression BMS-790052 Daclatasvir and F Promotion of tumor growth with K Correlated body F monoclonal anti-ErbB 2 with differential cellular’re Recording. Proc Natl Acad Sci U.S. A. 1995, 92:3353 3357th Hynes NE, Lane HA. Breast cancer and Myc: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase. Mammary gland neoplasia J Biol 2001, 6:141 150th Iwata H, Toi M, Fujiwara Y, Ito Y, Fujii H, Nakamura S, K aogi, Zaks T, Sasaki Y, Takashima S. Phase II study of lapatinib in patients with advanced or metastatic breast cancer. San Antonio Br Can Symp.
2006 No. 1091st Izumi Y, Xu L, di TE, Fukumura D, Jain RK. Tumour biology: Herceptin acts in an anti-angiogenic cocktail. Nature. 2002, 416:279 280th Jani JP, Barbacci EG, S Bhattacharya, Boos C, Campbell M, Clark T, K Coleman, R Connell, T. Cosker Tivozanib discovery and development, PO Box 724714, a selective inhibitor of the tyrosine kinase receptor HER2. Proc Amer Soc Clin Onc. 2004a, 22 # 3122nd Jani JP, Barbacci EG, S Bhattacharya, JD Moyer. CP 724 714, a novel inhibitor of the erbB2 receptor tyrosine kinase for the treatment of cancer. Proc Am Assoc Can Res 2004b, 45 # 4637th Juhl H, Downing SG, Wellstein A, F. Czubayko SA HER-2/neu is to limit the growth of ovarian cancer. Loss of ribozyme targeting of HER-2/neu SA. J Biol Chem 1997, 272:29482 29486.
Kiewe P, S Hasmuller, Kahlert S, M Heinrigs, Rack B, Marme A, et al. Phase I of the fight against HER2 ertumaxomab trifunctional anti-CD3 x in metastatic breast cancer. Clin Cancer Res 2006, 12:3085 3091st K K King CR, Kraus MH, Aaronson SA. The amplification of a novel gene associated with erbB v human mammary carcinoma. Science. 1985, 229:974 976th Kita Y, Tseng J, Horan T, Wen J, Philo J, Chang D, et al. The ErbB receptor activation induces Ver apoptosis and cell morphology changes by monoclonal anti-Her2 Rpern. Biochem Biophys Res Commun. 1996, 226:59 LN Klapper 69th, Vaisman N, Hurwitz E, Pinkas Kramarski R, Yarden Y, Sela M. rpern A subclass of monoclonal Rpers against ErbB tumorinhibitory Bridges Bl 2/HER2 more talk with growth factor receptors. Oncogene.
1997, 14:2099 2109th Page 16 Moasser Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. The activity of t T of kinase inhibitor lapatinib two papers against the HER-2 overexpression and trastuzumab breast cancer cells. Cancer Res 2006, 66:1630 1639th Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, et al. Combination immunotherapy with Herceptin for patients with HER2 expression. Anticancer Res 2003, 23:4443 4449th PS Kumar, Pegram M. HER2 epitopes. Semin Oncol. 2006, 33:386 391st Kurokawa H, Lenferink AE, Simpson JF, Pisacane IP Sliwkowski MX, Forbes JT, et al. Overexpress inhibition of protein kinase kinase and mitogen-activated HER2 HER2/neu improved over tamoxifen, tamoxifen-resistant breast cancer cells. Cancer Res 2000, 60:5887 5894th Kwak EL, Sordella R, Bell DW, Godin Heymann N, Okimoto RA, Brannigan BW, et al. Bypassed irreversible inhibitors of the EGF receptor may acquired resistanc